Navigation Links
Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling

Intercept Pharmaceuticals is Advancing Bile Acid-Derived Small Molecules

with Potential Applications in Treating Metabolic Diseases

NEW YORK, Aug. 7 /PRNewswire/ -- Historically, bile acids have been recognized primarily as natural detergents that regulate the absorption of dietary lipids and cholesterol homeostasis. However, recent research advances provide evidence that bile acids have broader systemic endocrine functions, acting as important mediators of glucose metabolism and insulin signaling. The featured article in the current issue of Nature Reviews Drug Discovery (Vol. 7, Number 8, August 2008) describes why bile acid receptors are promising targets for drug development in obesity, type 2 diabetes, atherosclerosis and other chronic metabolic disorders such as nonalcoholic steatohepatitis.

Highlights of the article, "Targeting bile acid signaling for metabolic diseases," authored by Drs. Charles Thomas, Roberto Pellicciari, Mark Pruzanski, Johan Auwerx and Kristina Schoonjans, include:

-- Bile acids serve as metabolic integrators, activating major signaling pathways regulated by nuclear hormone receptors including the farnesoid X receptor (FXR) and G protein-coupled receptors (GPCRs) such as TGR5.

-- Bile acids play a major role in lipid metabolism and homeostasis. For example, bile acid activation of FXR results in a decrease in serum triglyceride levels.

-- The activation of TGR5 by bile acids increases energy expenditure and reduces diet-induced obesity. Conversely, "knockout" animal models engineered to lack TGR5 show a tendency towards weight gain.

-- Bile acids have broad effects on glucose homeostasis, including a decrease in gluconeogenesis (glucose synthesis by the liver). These effects have been attributed primarily to activation of FXR. Additionally, mice that lack FXR have impaired glucose tolerance and are insulin-resistant.

Dr. Schoonjans, Ph.D., a group leader at the Ecole Polytechnique Federale de Lausanne commented, "Our research efforts have uncovered a number of endocrine effects mediated by bile acids acting on receptors such as FXR and TGR5. This review is one of the first to provide a comprehensive summary of what is now known about bile acid signaling and its relevance for metabolic function. From this broad viewpoint, we can see the potential for identifying important new therapeutics that can address a number of important disorders."

Dr. Pruzanski, founder, President and CEO of Intercept Pharmaceuticals, commented, "At Intercept, we have proprietary insight into the rational design of potent FXR and TGR5 agonists derived from bile acid scaffolds. To date, we have advanced our lead compound, INT-747, a first-in-class FXR agonist, into three ongoing Phase II trials. The innovative research being reported in the current issue of Nature Reviews provides additional support for our programs, and we look forward to reporting the progress of our discovery and development efforts in the appropriate forums."

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's scientists and affiliated researchers have published extensively on the role of bile acid signaling via the nuclear hormone receptor FXR and the G protein-coupled receptor TGR5. These receptors are key mediators of energy homeostasis and are involved in maintaining integral functions of the liver, intestine and kidney, organs exposed to bile acid flux. The company's chemocentric discovery programs are based on proprietary expertise in the rational design and synthesis of natural and synthetic small molecule derivatives targeting FXR, TGR5 and other related targets. For more information on Intercept, please visit the company's website at

SOURCE Intercept Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
2. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
3. Brain Signature for Cigarette Cravings Identified
4. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
5. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
6. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
7. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
8. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
9. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
10. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
11. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
Post Your Comments:
(Date:11/30/2015)... 2015 --> --> ... Market by Product (Soft Tissue, All Tissue, Dental Welding Lasers), ... and Geography - Global Forecast to 2020", published by MarketsandMarkets, ... a CAGR of 5.2% during the forecast period from 2015 ... and 62 Figures spread through 167 P ages and ...
(Date:11/30/2015)... ST. LOUIS , Nov. 30, 2015  Premera ... today announced an early renewal of the companies, long-standing ... will now extend through at least 2019. ... pharmacy benefit manager capabilities during a competitive review and ... offer the best health plan integration and deliver the ...
(Date:11/30/2015)... 2015 Booth #4303 – The Imaging Components business ... a broader array of products in a new booth (#4303) ... North America in Chicago ... feature X-ray components "At the Heart of Imaging." Products will ... from Varian,s Claymount brand, and computer-aided diagnostic software from MeVis ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... comparison chart and ingredient list of its hemorrhoid ointment to its website. , ... pain relief for people suffering from hemorrhoids. Adding the comparison chart and ingredient ...
(Date:11/30/2015)... ... November 30, 2015 , ... Advocare Orthopedic ... orthopedic care. Led by John Vitolo, M.D., the center offers their patients ... team at Advocare Orthopedic & Sports Medicine is ready to help their patients ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved ... grandfather graduated from Tufts School of Dental Medicine in 1935. His father graduated ... Isola family being in dentistry as well as their commitment and passion to the ...
(Date:11/30/2015)... ... November 30, 2015 , ... Two years ago, Debbie Gregory, ... the David Lynch Foundation, learning Transcendental Meditation (TM). After encouraging a number of ... walk so that she could talk the talk. , TM is becoming one of ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as supporting ... so for a child’s exposure limits. , The original Nov 2015 CR story ...
Breaking Medicine News(10 mins):